ZIOPHARM Oncology

ZIOPHARM Oncology, Inc.
Investor Relations Department
One First Ave., Parris Building, # 34
Navy Yard Plaza
Boston, MA 02199
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: ZIOP	
Last Trade:	6.84
Trade Time:	4:00 PM ET Apr 24, 2017
Change:	0.05 (+0.736%)
Day Range	6.79 - 6.93
52-Week Range	4.45 - 8.72
Volume	707,319

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

… (more)

Stock Performance



Press Releases [View all]

Apr 24, 2017
ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET

Apr 20, 2017
ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting

Apr 3, 2017
Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Platform Empowered by Membrane-Bound IL-15 Under RheoSwitch Therapeutic System® Control

Mar 27, 2017
ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma

Mar 27, 2017
ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications

Upcoming Events [View all]

May 1, 2017 4:30 PM ET
Ziopharm First Quarter 2017 Financial Results Conference Call

Financials [View all]

Feb 16, 2017
Annual Report (10-K)

Apr 28, 2016
Proxy Statement (DEF 14A)

Nov 9, 2016
Quarterly Report (10-Q)

Aug 9, 2016
Quarterly Report (10-Q)

May 10, 2016
Quarterly Report (10-Q)